Publications by authors named "Thomas B Neff"

Claim this Profile
R
Retraction notice to "Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis." . 2021;6:613-623.
Robert Provenzano, Steven Fishbane, Lynda Szczech, Robert Leong, Khalil G Saikali, Thomas B Neff

Kidney Int Rep· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
Robert Provenzano, Evgeny Shutov, Liubov Eremeeva, Svitlana Korneyeva, Lona Poole, Thomas B Neff

Nephrol Dial Transplant· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
Robert Provenzano, Lynda Szczech, Robert Leong, Khalil G Saikali, Ming Zhong, Thomas B Neff

Clin J Am Soc Nephrol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.
Robert Provenzano, Steven Fishbane, Lynda Szczech, Robert Leong, Khalil G Saikali, Thomas B Neff

Kidney Int Rep· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Robert Provenzano, James Tumlin, Raja Zabaneh, James Chou, Stefan Hemmerich, Thomas B Neff

J Clin Pharmacol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Ughetta Del Balzo, Pierre E Signore, Gail Walkinshaw, Todd W Seeley, Mitchell C Brenner, Thomas B Neff

J Pharmacol Exp Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Nan Chen, Jiaqi Qian, Jianghua Chen, Xueqing Yu, Changlin Mei, Thomas B Neff

Nephrol Dial Transplant· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer.
Todd W Seeley, Mark D Sternlicht, Stephen J Klaus, Thomas B Neff, David Y Liu

Hypoxia (Auckl)· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Robert Provenzano, Anatole Besarab, Steven Wright, Sohan Dua, Steven Zeig, Thomas B Neff

Am J Kidney Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Robert Provenzano, Anatole Besarab, Chao H Sun, Susan A Diamond, John H Durham, Thomas B Neff

Clin J Am Soc Nephrol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
Anatole Besarab, Elena Chernyavskaya, Igor Motylev, Evgeny Shutov, Lalathaksha M Kumbar, Thomas B Neff

J Am Soc Nephrol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Anatole Besarab, Robert Provenzano, Joachim Hertel, Raja Zabaneh, Stephen J Klaus, Thomas B Neff

Nephrol Dial Transplant· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria.
Sharon G Adler, Sherwyn Schwartz, Mark E Williams, Carlos Arauz-Pacheco, Warren K Bolton, Thomas B Neff

Clin J Am Soc Nephrol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis